loader
Please Wait
Applying Filters...

Annual Sales of Vilanterol Trifenatate reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 223,171Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 5Anoro Ellipta

02 5Trelegy Ellipta

PharmaCompass
Left Arrow
Right Arrow

01

Brand Name : Trelegy Ellipta

Vilanterol Trifenatate

arrow
Luxepack
Not Confirmed

Brand Name : Trelegy Ellipta

arrow
Luxepack
Not Confirmed

Vilanterol Trifenatate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 1,135

2019 Revenue in Millions : 718

Growth (%) : 58

blank

02

Brand Name : Anoro Ellipta

Vilanterol

arrow
Luxepack
Not Confirmed

Brand Name : Anoro Ellipta

arrow
Luxepack
Not Confirmed

Vilanterol

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2020 Revenue in Millions : 758

2019 Revenue in Millions : 713

Growth (%) : 6

blank

03

Brand Name : Trelegy Ellipta

Vilanterol Trifenatate

arrow
Luxepack
Not Confirmed

Brand Name : Trelegy Ellipta

arrow
Luxepack
Not Confirmed

Vilanterol Trifenatate

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 1,647

2020 Revenue in Millions : 1,122

Growth (%) : 49

blank

04

Brand Name : Anoro Ellipta

Vilanterol

arrow
Luxepack
Not Confirmed

Brand Name : Anoro Ellipta

arrow
Luxepack
Not Confirmed

Vilanterol

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2021 Revenue in Millions : 682

2020 Revenue in Millions : 749

Growth (%) : -8

blank

05

Brand Name : Anoro Ellipta

Vilanterol

arrow
Luxepack
Not Confirmed

Brand Name : Anoro Ellipta

arrow
Luxepack
Not Confirmed

Vilanterol

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2022 Revenue in Millions : 595

2021 Revenue in Millions : 682

Growth (%) : -13

blank

06

Brand Name : Trelegy Ellipta

Vilanterol Trifenatate

arrow
Luxepack
Not Confirmed

Brand Name : Trelegy Ellipta

arrow
Luxepack
Not Confirmed

Vilanterol Trifenatate

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2022 Revenue in Millions : 2,132

2021 Revenue in Millions : 1,647

Growth (%) : 29

blank

07

Brand Name : Trelegy Ellipta

Vilanterol Trifenatate

arrow
Luxepack
Not Confirmed

Brand Name : Trelegy Ellipta

arrow
Luxepack
Not Confirmed

Vilanterol Trifenatate

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2023 Revenue in Millions : 2,377

2022 Revenue in Millions : 2,132

Growth (%) : 27

blank

08

Brand Name : Anoro Ellipta

Vilanterol

arrow
Luxepack
Not Confirmed

Brand Name : Anoro Ellipta

arrow
Luxepack
Not Confirmed

Vilanterol

Main Therapeutic Indication : Respiratory Diseases

Currency : USD

2023 Revenue in Millions : 601

2022 Revenue in Millions : 595

Growth (%) : 15

blank

09

Brand Name : Anoro Ellipta

Vilanterol

arrow
Luxepack
Not Confirmed

Brand Name : Anoro Ellipta

arrow
Luxepack
Not Confirmed

Vilanterol

Main Therapeutic Indication : Respiratory Disorders

Currency : USD

2019 Revenue in Millions : 637

2018 Revenue in Millions : 590

Growth (%) : 8

blank

10

Brand Name : Trelegy Ellipta

Vilanterol Trifenatate

arrow
Luxepack
Not Confirmed